GB1103135A - Prevention of anaphylactic shock - Google Patents
Prevention of anaphylactic shockInfo
- Publication number
- GB1103135A GB1103135A GB14934/66A GB1493466A GB1103135A GB 1103135 A GB1103135 A GB 1103135A GB 14934/66 A GB14934/66 A GB 14934/66A GB 1493466 A GB1493466 A GB 1493466A GB 1103135 A GB1103135 A GB 1103135A
- Authority
- GB
- United Kingdom
- Prior art keywords
- pyridyl
- beta
- anaphylactic shock
- amine
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 206010002199 Anaphylactic shock Diseases 0.000 title abstract 4
- 208000003455 anaphylaxis Diseases 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title 1
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- -1 methapyrilone Chemical compound 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 229930182555 Penicillin Natural products 0.000 abstract 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 230000000172 allergic effect Effects 0.000 abstract 2
- 150000001412 amines Chemical class 0.000 abstract 2
- 208000010668 atopic eczema Diseases 0.000 abstract 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 abstract 2
- 231100000252 nontoxic Toxicity 0.000 abstract 2
- 230000003000 nontoxic effect Effects 0.000 abstract 2
- 229940049954 penicillin Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- WFNAKBGANONZEQ-UHFFFAOYSA-N 1-[(4-chlorophenyl)-phenylmethyl]-4-methylpiperazine Chemical compound C1CN(C)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 WFNAKBGANONZEQ-UHFFFAOYSA-N 0.000 abstract 1
- DQKQDUXKROXADZ-UHFFFAOYSA-N 2-methyl-1-pyridin-2-ylpropan-1-amine Chemical compound CC(C)C(N)C1=CC=CC=N1 DQKQDUXKROXADZ-UHFFFAOYSA-N 0.000 abstract 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 abstract 1
- LDYJXVUOVPVZKA-UHFFFAOYSA-N Methaphenilene Chemical compound C=1C=CC=CC=1N(CCN(C)C)CC1=CC=CS1 LDYJXVUOVPVZKA-UHFFFAOYSA-N 0.000 abstract 1
- GULNIHOSWFYMRN-UHFFFAOYSA-N N'-[(4-methoxyphenyl)methyl]-N,N-dimethyl-N'-(2-pyrimidinyl)ethane-1,2-diamine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=NC=CC=N1 GULNIHOSWFYMRN-UHFFFAOYSA-N 0.000 abstract 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 abstract 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 229960000725 brompheniramine Drugs 0.000 abstract 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229960000428 carbinoxamine Drugs 0.000 abstract 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 abstract 1
- 229960004831 chlorcyclizine Drugs 0.000 abstract 1
- 229950005434 chloropyrilene Drugs 0.000 abstract 1
- XAEXSWVTEJHRMH-UHFFFAOYSA-N chloropyrilene Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=C(Cl)S1 XAEXSWVTEJHRMH-UHFFFAOYSA-N 0.000 abstract 1
- 229960003291 chlorphenamine Drugs 0.000 abstract 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 abstract 1
- 229960003564 cyclizine Drugs 0.000 abstract 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960002691 dexbrompheniramine Drugs 0.000 abstract 1
- ZDIGNSYAACHWNL-HNNXBMFYSA-N dexbrompheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Br)C=C1 ZDIGNSYAACHWNL-HNNXBMFYSA-N 0.000 abstract 1
- 229960001882 dexchlorpheniramine Drugs 0.000 abstract 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 abstract 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 abstract 1
- 229960004993 dimenhydrinate Drugs 0.000 abstract 1
- 229960000520 diphenhydramine Drugs 0.000 abstract 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 abstract 1
- 229960000879 diphenylpyraline Drugs 0.000 abstract 1
- OWQUZNMMYNAXSL-UHFFFAOYSA-N diphenylpyraline Chemical compound C1CN(C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 OWQUZNMMYNAXSL-UHFFFAOYSA-N 0.000 abstract 1
- 229960005178 doxylamine Drugs 0.000 abstract 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 abstract 1
- 229940050411 fumarate Drugs 0.000 abstract 1
- 229940050410 gluconate Drugs 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 229960001474 meclozine Drugs 0.000 abstract 1
- 229960000582 mepyramine Drugs 0.000 abstract 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 abstract 1
- 229950000498 methaphenilene Drugs 0.000 abstract 1
- 229960003534 phenindamine Drugs 0.000 abstract 1
- 229960001190 pheniramine Drugs 0.000 abstract 1
- WDYYVNNRTDZKAZ-XDHOZWIPSA-N pyrrobutamine Chemical compound C1=CC(Cl)=CC=C1C\C(C=1C=CC=CC=1)=C/CN1CCCC1 WDYYVNNRTDZKAZ-XDHOZWIPSA-N 0.000 abstract 1
- 229960002775 pyrrobutamine Drugs 0.000 abstract 1
- 239000007939 sustained release tablet Substances 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- 229960003785 thonzylamine Drugs 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- 229960003223 tripelennamine Drugs 0.000 abstract 1
- 229960001128 triprolidine Drugs 0.000 abstract 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45496765A | 1965-05-11 | 1965-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1103135A true GB1103135A (en) | 1968-02-14 |
Family
ID=23806815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB14934/66A Expired GB1103135A (en) | 1965-05-11 | 1966-04-04 | Prevention of anaphylactic shock |
Country Status (4)
| Country | Link |
|---|---|
| ES (1) | ES326590A1 (enExample) |
| FR (1) | FR6204M (enExample) |
| GB (1) | GB1103135A (enExample) |
| IL (1) | IL25514A (enExample) |
-
1966
- 1966-04-01 IL IL2551466A patent/IL25514A/en unknown
- 1966-04-04 GB GB14934/66A patent/GB1103135A/en not_active Expired
- 1966-05-11 ES ES0326590A patent/ES326590A1/es not_active Expired
- 1966-06-06 FR FR61017A patent/FR6204M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IL25514A (en) | 1970-05-21 |
| ES326590A1 (es) | 1967-07-01 |
| FR6204M (enExample) | 1968-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW492882B (en) | Cholinergic antagonist plaster composition | |
| BG106439A (en) | Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative | |
| AR032730A1 (es) | Desnaturalizantes para las sales aminas simpaticomimeticas | |
| KR960703589A (ko) | 사람 면역결핍 바이러스-프로테아제 억제제의 약제학적 조성물(Pharmaceutical composition of HIV-protease inhibitors) | |
| TW534816B (en) | Preservative system for topically administrable pharmaceutical compositions | |
| MX2025004371A (es) | Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4- tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma | |
| AR037490A1 (es) | Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos | |
| DE3267923D1 (de) | Novel n-(3-hydroxy-4-piperidinyl)benzamide derivatives | |
| DE602004016856D1 (de) | Hfc lösungsformulierungen enthaltend ein anticholinergikum | |
| ES2091441T3 (es) | Composicion farmaceutica. | |
| JP2013189450A5 (enExample) | ||
| ES2099094T3 (es) | Metodos y composiciones para tratamiento de interacciones hidrofobas patologicas en fluidos biologicos. | |
| AR042095A1 (es) | Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih | |
| BR0108584A (pt) | Formulações contendo um fármaco anticolinérgico para o tratamento da broncopneumopatia crÈnica obtrutiva | |
| PE20020694A1 (es) | Composiciones orales que tienen caracteristicas esteticas del consumidor mejoradas | |
| RU2462234C2 (ru) | Способы стабилизации окислительно нестабильных композиций | |
| ATE179884T1 (de) | Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen | |
| CA2924026C (en) | Deoxynojirimycin derivatives and methods of their using | |
| NO175405C (no) | Fremgangsmåte for fremstilling av et farmasöytisk preparat med sakte frigivelse, som ikke er et injeksjonsfluid | |
| AR029456A1 (es) | Forma triturada | |
| JP2023033557A (ja) | 複合目症状改善用眼科組成物 | |
| ES2092646T3 (es) | Metanoantracenos como antagonistas de dopamina. | |
| GB1114313A (en) | Pharmaceutical compositions | |
| PE20130814A1 (es) | Sales de benzimidazolil piridil eteres y formulaciones que las contienen | |
| GB1103135A (en) | Prevention of anaphylactic shock |